Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
TBPH

TBPH - Theravance Biopharma Inc Stock Price, Fair Value and News

9.56USD-0.12 (-1.24%)Market Closed

Market Summary

TBPH
USD9.56-0.12
Market Closed
-1.24%

TBPH Stock Price

View Fullscreen

TBPH RSI Chart

TBPH Valuation

Market Cap

464.9M

Price/Earnings (Trailing)

-10.39

Price/Sales (Trailing)

8.55

EV/EBITDA

-11.83

Price/Free Cashflow

-27.68

TBPH Price/Sales (Trailing)

TBPH Profitability

EBT Margin

-68.41%

Return on Equity

-21.85%

Return on Assets

-12.06%

Free Cashflow Yield

-3.61%

TBPH Fundamentals

TBPH Revenue

Revenue (TTM)

54.4M

Rev. Growth (Yr)

39.22%

Rev. Growth (Qtr)

-7.58%

TBPH Earnings

Earnings (TTM)

-44.8M

Earnings Growth (Yr)

47.19%

Earnings Growth (Qtr)

-37.06%

Breaking Down TBPH Revenue

Last 7 days

2.0%

Last 30 days

12.7%

Last 90 days

2.4%

Trailing 12 Months

-0.9%

How does TBPH drawdown profile look like?

TBPH Financial Health

Current Ratio

5.74

TBPH Investor Care

Buy Backs (1Y)

15.86%

Diluted EPS (TTM)

-0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202454.4M000
202351.3M51.3M54.5M0
202254.3M52.4M52.0M51.3M
202166.3M64.2M59.1M55.3M
202087.9M76.8M82.6M71.9M
201957.4M60.1M59.7M73.4M
201820.6M40.6M49.1M60.4M
201733.3M31.4M16.6M15.4M
201640.1M38.5M46.8M48.6M
201531.1M35.3M39.7M42.1M
20141.1M4.1M10.4M11.7M
2013104.3M78.5M52.7M26.9M
2012000130.1M

Tracking the Latest Insider Buys and Sells of Theravance Biopharma Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 10, 2024
farnum rhonda
sold
-36,000
9.00
-4,000
svp, comm & medical affairs
May 20, 2024
farnum rhonda
sold (taxes)
-84,338
9.1
-9,268
svp, comm & medical affairs
May 20, 2024
sawaf aziz
sold (taxes)
-78,578
9.1
-8,635
svp & chief financial officer
May 20, 2024
winningham rick e
sold (taxes)
-145,573
9.1
-15,997
chief executive officer
May 20, 2024
miller aine
sold (taxes)
-47,329
9.1
-5,201
svp, dev & head of ire office
May 20, 2024
grimaud brett a.
sold (taxes)
-84,338
9.1
-9,268
svp, gen counsel and secretary
May 15, 2024
winningham rick e
acquired
20,369
9.85
2,068
chief executive officer
May 08, 2024
grant jeremy t
acquired
-
-
10,537
-
May 08, 2024
gray susannah
acquired
-
-
10,537
-

1–10 of 50

Which funds bought or sold TBPH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-40.38
-37,514
48,446
0.01%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
reduced
-13.11
-195
899
-%
Jul 18, 2024
Assenagon Asset Management S.A.
sold off
-100
-360,289
-
-%
Jul 12, 2024
SG Americas Securities, LLC
reduced
-22.51
-503,000
1,377,000
0.01%
Jul 10, 2024
CWM, LLC
added
94.98
7,000
15,000
-%
Jul 08, 2024
Westend Capital Management, LLC
sold off
-
-
-
-%
Jul 02, 2024
GAMMA Investing LLC
reduced
-34.56
-1,485
2,408
-%
Jul 01, 2024
Legal & General Group Plc
added
4.02
-96,230
470,199
-%
May 20, 2024
Pacific Center for Financial Services
unchanged
-
-129
512
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-90.95
-3,874,390
301,464
-%

1–10 of 47

Are Funds Buying or Selling TBPH?

Are funds buying TBPH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TBPH
No. of Funds

Unveiling Theravance Biopharma Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 11, 2024
odre 2005 slu
0.0%
0
SC 13G/A
May 03, 2024
madison avenue partners, lp
17.5%
8,511,350
SC 13G/A
Mar 05, 2024
weiss asset management lp
15.5%
7,457,060
SC 13D/A
Feb 14, 2024
irenic capital management lp
5.5%
2,760,948
SC 13G
Feb 13, 2024
vanguard group inc
7.01%
3,489,262
SC 13G/A
Feb 08, 2024
blackrock inc.
9.2%
4,584,596
SC 13G/A
Aug 14, 2023
weiss asset management lp
14.%
7,457,060
SC 13D/A
Jul 10, 2023
baupost group llc/ma
12.84%
7,419,226
SC 13G/A
Apr 12, 2023
weiss asset management lp
11.%
7,457,060
SC 13D
Feb 14, 2023
madison avenue partners, lp
10.4%
7,012,226
SC 13G/A

Recent SEC filings of Theravance Biopharma Inc

View All Filings
Date Filed Form Type Document
Jul 12, 2024
4
Insider Trading
Jun 11, 2024
SC 13G/A
Major Ownership Report
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 22, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 15, 2024
10-Q
Quarterly Report
May 13, 2024
8-K
Current Report

Peers (Alternatives to Theravance Biopharma Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
46.4B
6.8B
-9.08% -2.89%
-7.78
6.94
-64.45% -224.75%
30.1B
2.0B
54.57% 18.06%
-90.59
15.02
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.0B
2.5B
-0.07% -3.94%
77.72
6.46
13.74% 186.89%
14.8B
3.8B
7.23% 2.92%
19.84
3.93
8.58% 129.81%
MID-CAP
4.9B
107.9M
-5.14% -24.06%
-8.96
48.09
54.84% -28.31%
4.6B
524.1M
-5.19% 10.95%
-11.05
8.8
394.93% 39.61%
4.0B
251.0M
11.60% 13.99%
-13.6
16.05
73.58% -86.73%
3.5B
240.7M
20.06% -18.70%
-7.43
12.77
-1.03% -213.92%
2.9B
813.8M
19.30% -43.25%
-1.7K
3.6
56.43% 98.83%
1.9B
996.6M
0.36% 71.71%
-4.87
1.95
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
13.16% 23.83%
30.73
4.86
60.38% -34.49%
618.2M
881.7K
32.05% 709.09%
-18.31
481.06
-77.61% 33.36%
260.1M
4.2M
17.29% 54.94%
-2.08
62.54
-66.30% 48.24%
18.8M
2.1M
-4.39% -80.54%
-0.81
7.61
-13.45% 69.54%

Theravance Biopharma Inc News

Latest updates
American Banking and Market News28 hours ago
Yahoo Finance UK15 Jul 202411:20 am
American Banking and Market News13 Jul 202406:19 am

Theravance Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q32023Q22023Q12022Q42022Q32022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-7.6%14,503,00015,693,00013,749,00010,417,00014,649,00012,451,00011,750,50011,050,00013,196,00014,946,00013,194,00012,914,00014,257,00018,730,00018,257,00015,008,00019,862,00029,499,00012,427,00026,150,0005,338,000
Operating Expenses5.1%25,710,00024,453,00029,872,00035,329,00032,081,00021,595,000-37,929,00051,698,00071,113,00066,809,00077,024,00098,149,00095,220,00094,872,00087,184,00092,338,000100,071,00077,628,00068,626,00079,004,000
  S&GA Expenses3.7%16,742,00016,142,00019,278,00019,183,00016,732,00016,277,000-15,890,00016,222,00017,842,00021,516,00021,299,00025,931,00030,550,00029,925,00027,501,00024,780,00026,325,00033,046,00025,622,00022,227,00025,186,000
  R&D Expenses7.9%8,968,0008,311,0009,425,00014,572,00015,348,0009,867,000-14,924,00023,253,00031,226,00043,739,00051,093,00067,599,00065,165,00067,371,00062,404,00066,013,00067,025,00052,006,00046,399,00053,818,000
EBITDA Margin33.9%-0.64-0.97-1.18-1.31-1.62-2.79-3.53-3.51-3.76-4.23-4.52-4.29-4.32--------
Interest Expenses3.3%629,000609,000568,000550,000550,0001,545,000-2,137,0002,137,000-7,468,5002,136,00011,612,00011,873,000-24,358,00011,573,00011,391,0009,941,0008,035,0008,068,0007,901,0007,858,000
Income Taxes-9.9%1,262,0001,400,0001,500,000-395,000-3,000-507,000--5,000524,0001,756,000-7,000-220,000227,000-8,799,00093,00039,000147,00049,000-5,552,000201,00080,000
Earnings Before Taxes-37.2%-10,402,000-7,583,000-14,187,000-22,483,000-14,259,000-16,023,000--22,798,000-39,735,000-67,597,000-55,917,000-52,625,000-79,452,000-84,039,000-73,550,000-62,848,000-82,906,000-65,557,000-63,983,000-39,637,000-72,500,000
EBT Margin36.3%-0.68-1.07-1.31-1.47-1.81-2.83-3.58-3.55-3.98-4.62-4.60-4.51-4.53--------
Net Income-30.3%-11,664,000-8,950,000-15,645,000-22,088,000-10,362,000916,631,00031,629,000-8,191,000-25,946,000-32,034,000-35,308,000-52,405,000-79,679,000-58,434,000-73,643,000-62,887,000-83,053,000-65,606,000-58,431,000-39,838,000-72,580,000
Net Income Margin21.3%-0.82-1.0516.9417.8518.1117.68-0.66-1.94-2.69-3.61-3.82-4.12-4.15--------
Free Cashflow67.3%-1,022,000-3,124,000-13,074,000-11,859,000-124,693,000-22,775,000-15,368,000-15,368,000-26,707,000-43,072,000-46,084,000-50,751,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Assets-2.8%37138241444753960776372.00361355375403429375469512564605409445492
  Current Assets-6.9%124134162192261353512-15520525029733329339345149853437.00356426
    Cash Equivalents36.1%54.0040.0072.0010618829941929.0087.0094.0091.0012120511481.0093.0010533359.00102178
  Net PPE-3.9%9.009.009.0010.0012.0012.0012.00-13.0013.0014.0016.0017.0017.0016.0015.0014.0014.0013.0012.0013.00
  Current Liabilities-12.5%22.0025.0025.0025.0026.0029.00142-33.0044.0059.0066.0067.0086.0012410410798.003.00109110
Shareholder's Equity-3.8%205213246280371442481--------------
  Retained Earnings-1.3%-920-909-900-891-876-853-843--1,760-1,751-1,726-1,694-1,658-1,606-1,526-1,468-1,394-1,331-1,248-1,182-1,124
  Additional Paid-In Capital0.3%1,1261,1221,1471,1721,2471,2961,324-1,4101,4011,3871,3701,3581,2331,2231,2071,1921,1731,0251,000987
Shares Outstanding1.0%49.0048.0051.0054.0063.0065.0076.0076.0076.0075.0074.0068.0065.00--------
Float----459----677---882---1,280---893
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-19.7%-1.02-0.85-2.49-12.44-11.22-124-22.14-14.73-26.07-42.43-45.45-50.11-69.86-64.92-77.03-53.35-55.10-64.35-44.62-48.03-81.19
  Share Based Compensation-10.2%5.006.006.006.007.007.009.0010.0015.0017.0014.0015.0016.0016.0016.0017.0015.0024.0013.0011.0012.00
Cashflow From Investing2615.2%17.00-0.68-0.0211.00-43.0539.001,0758.0032.0011.00-35.7936.0011452.0067.00-17668.0014.00-23.66-1.30-72.16
Cashflow From Financing94.4%-1.72-30.61-31.40-80.68-56.24-35.47-7220.00-1.450.00-2.29105-11.291.00-0.962.00261-1.54-0.134.00-1.43
  Buy Backs-98.5%0.0030.0031.0081.0055.00-94.00--------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TBPH Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 14,503$ 10,417
Expenses:  
Research and development[1]8,96814,572
Selling, general and administrative[1]16,74219,183
Restructuring and related expenses[1] 1,574
Total expenses25,71035,329
Loss from operations(11,207)(24,912)
Interest expense (non-cash)(629)(550)
Interest income and other income (expense), net1,4342,979
Loss before income taxes(10,402)(22,483)
Provision for income tax expense (benefit)1,262(395)
Net loss(11,664)(22,088)
Other comprehensive loss:  
Net unrealized gain on available-for-sale investments2466
Total comprehensive loss$ (11,640)$ (22,022)
Net loss per share:  
Net loss - basic (in dollars per share)$ (0.24)$ (0.35)
Net loss - diluted (in dollars per share)$ (0.24)$ (0.35)
Shares used to compute net income (loss) per share - basic48,28362,934
Shares used to compute net income (loss) per share - diluted48,28362,934
Viatris collaboration agreement  
Revenue:  
Total revenue$ 14,503$ 10,411
Collaboration revenue  
Revenue:  
Total revenue $ 6
[1]Amounts include share-based compensation expense as follows:

TBPH Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 53,835$ 39,545
Short-term marketable securities46,14062,881
Receivables from collaborative arrangements14,66417,474
Prepaid clinical and development services2,0862,038
Other prepaid and current assets7,56911,603
Total current assets124,294133,541
Property and equipment, net8,7179,068
Operating lease assets35,36436,287
Future contingent milestone and royalty assets194,200194,200
Restricted cash836836
Other assets7,8968,067
Total assets371,307381,999
Current liabilities:  
Accounts payable1,6861,524
Accrued personnel-related expenses4,4756,443
Accrued clinical and development expenses1,3992,246
Accrued general and administrative expenses2,4762,900
Operating lease liabilities4,0633,923
Tenant improvement payable to subleasee6,4906,490
Other accrued liabilities1,0731,241
Total current liabilities21,66224,767
Long-term operating lease liabilities43,84045,236
Future royalty payment contingency28,41727,788
Unrecognized tax benefits67,07565,294
Other long-term liabilities5,4455,919
Commitments and contingencies (Note 10)
Shareholders' Equity  
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 48,566 and 48,091 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital1,125,6771,122,164
Accumulated other comprehensive loss(41)(65)
Accumulated deficit(920,768)(909,104)
Total shareholders' equity204,868212,995
Total liabilities and shareholders' equity$ 371,307$ 381,999
TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
 CEO
 WEBSITEtheravance.com
 INDUSTRYBiotechnology
 EMPLOYEES111

Theravance Biopharma Inc Frequently Asked Questions


What is the ticker symbol for Theravance Biopharma Inc? What does TBPH stand for in stocks?

TBPH is the stock ticker symbol of Theravance Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Theravance Biopharma Inc (TBPH)?

As of Fri Jul 19 2024, market cap of Theravance Biopharma Inc is 464.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers.

What is the fair value of TBPH stock?

You can check TBPH's fair value in chart for subscribers. The fair value of Theravance Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Theravance Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TBPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Theravance Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether TBPH is over valued or under valued. Whether Theravance Biopharma Inc is cheap or expensive depends on the assumptions which impact Theravance Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TBPH.

What is Theravance Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, TBPH's PE ratio (Price to Earnings) is -10.39 and Price to Sales (PS) ratio is 8.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TBPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Theravance Biopharma Inc's stock?

In the past 10 years, Theravance Biopharma Inc has provided -0.115 (multiply by 100 for percentage) rate of return.